ZA200804868B - Anti-OX40L antibodies and methods using same - Google Patents
Anti-OX40L antibodies and methods using sameInfo
- Publication number
- ZA200804868B ZA200804868B ZA200804868A ZA200804868A ZA200804868B ZA 200804868 B ZA200804868 B ZA 200804868B ZA 200804868 A ZA200804868 A ZA 200804868A ZA 200804868 A ZA200804868 A ZA 200804868A ZA 200804868 B ZA200804868 B ZA 200804868B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- same
- ox40l antibodies
- ox40l
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75137705P | 2005-12-16 | 2005-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200804868B true ZA200804868B (en) | 2009-10-28 |
Family
ID=38616368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200804868A ZA200804868B (en) | 2005-12-16 | 2006-12-15 | Anti-OX40L antibodies and methods using same |
Country Status (18)
Country | Link |
---|---|
US (2) | US7812133B2 (xx) |
EP (1) | EP1973949A2 (xx) |
JP (1) | JP2009519718A (xx) |
KR (1) | KR20080080639A (xx) |
CN (1) | CN101374865A (xx) |
AR (1) | AR057253A1 (xx) |
AU (1) | AU2006343459A1 (xx) |
BR (1) | BRPI0621065A2 (xx) |
CA (1) | CA2633602A1 (xx) |
CR (1) | CR10069A (xx) |
EC (1) | ECSP088543A (xx) |
IL (1) | IL191820A0 (xx) |
MA (1) | MA30153B1 (xx) |
NO (1) | NO20083147L (xx) |
RU (1) | RU2426744C2 (xx) |
TW (1) | TW200732349A (xx) |
WO (1) | WO2007133290A2 (xx) |
ZA (1) | ZA200804868B (xx) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
EP2041756B1 (en) | 2006-07-14 | 2015-05-13 | FEI Company | A multi-source plasma focused ion beam system |
JP2010518873A (ja) * | 2007-02-27 | 2010-06-03 | ジェネンテック, インコーポレイテッド | アンタゴニスト抗ox40抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用 |
US20090309617A1 (en) * | 2007-08-24 | 2009-12-17 | Ye Fang | Biosensor antibody functional mapping |
WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
US20120020960A1 (en) * | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
CN103221427B (zh) | 2010-08-23 | 2016-08-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
EA030851B1 (ru) | 2011-04-21 | 2018-10-31 | Бристол-Майерс Сквибб Компани | Полипептиды антитела, которые антагонизируют cd40 |
RU2562874C1 (ru) * | 2011-08-23 | 2015-09-10 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела против ох40 и способы их применения |
EP3043810B1 (en) | 2013-09-09 | 2019-10-23 | CanImGuide Therapeutics AB | Immune system modulators |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
JP2017165652A (ja) * | 2014-06-30 | 2017-09-21 | 国立大学法人東北大学 | 新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬 |
EP3194445A4 (en) * | 2014-08-04 | 2018-05-23 | Baylor Research Institute | Antagonistic anti-ox40l antibodies and methods of their use |
US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
CA2968642A1 (en) * | 2015-03-03 | 2016-09-09 | Kymab Limited | Antibodies, uses & methods |
US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
US9434785B1 (en) * | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
DK3265117T3 (da) | 2015-03-06 | 2021-02-08 | Canimguide Therapeutics Ab | Immunsystemmodulatorer og præparater |
CN108137686B (zh) | 2015-05-07 | 2022-06-17 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
DE102016105069A1 (de) | 2016-03-18 | 2017-09-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Antivirale Immuntherapie durch Membranrezeptorligation |
US11065301B2 (en) | 2016-04-15 | 2021-07-20 | Pontificia Universidad Catolica De Chile | Pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and use thereof |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
AU2017359467A1 (en) | 2016-11-09 | 2019-05-02 | Agenus Inc. | Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
WO2019100320A1 (en) | 2017-11-24 | 2019-05-31 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ox40 antibodies and uses thereof |
WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
TW202330023A (zh) * | 2021-08-10 | 2023-08-01 | 英商科馬布有限公司 | 異位性皮膚炎之治療 |
IL314314A (en) * | 2022-02-09 | 2024-09-01 | Petmedix Ltd | Therapeutic antibodies |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
JP3914342B2 (ja) * | 1997-09-25 | 2007-05-16 | 武田薬品工業株式会社 | gp34結合阻害物を有効成分として含有する医薬組成物 |
WO2001094586A2 (en) * | 2000-06-06 | 2001-12-13 | Idec Pharmaceuticals Corporation | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
FR2822846B1 (fr) * | 2001-04-03 | 2004-01-23 | Technopharm | Procede de preparation et de selection d'anticorps |
GB0123276D0 (en) | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
JP3926596B2 (ja) | 2001-09-28 | 2007-06-06 | 独立行政法人科学技術振興機構 | Ox40l遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物 |
WO2003059245A2 (en) * | 2001-12-18 | 2003-07-24 | J & J Research Pty Ltd | Method of treating asthma |
IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
CA2496795C (en) | 2002-08-28 | 2014-06-03 | Paul B. Burton | Compositions and methods for treating cardiovascular disease |
US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
US20060002929A1 (en) * | 2004-03-23 | 2006-01-05 | Khare Sanjay D | Monoclonal antibodies |
JP2006081061A (ja) * | 2004-09-13 | 2006-03-23 | Alpine Electronics Inc | 音声出力装置及び音声/映像出力装置 |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
JP2010518873A (ja) | 2007-02-27 | 2010-06-03 | ジェネンテック, インコーポレイテッド | アンタゴニスト抗ox40抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用 |
-
2006
- 2006-12-15 RU RU2008129111/10A patent/RU2426744C2/ru not_active IP Right Cessation
- 2006-12-15 CN CNA2006800529729A patent/CN101374865A/zh active Pending
- 2006-12-15 EP EP06851330A patent/EP1973949A2/en not_active Withdrawn
- 2006-12-15 JP JP2008545995A patent/JP2009519718A/ja not_active Withdrawn
- 2006-12-15 CA CA002633602A patent/CA2633602A1/en not_active Abandoned
- 2006-12-15 AU AU2006343459A patent/AU2006343459A1/en not_active Abandoned
- 2006-12-15 US US12/097,733 patent/US7812133B2/en active Active
- 2006-12-15 ZA ZA200804868A patent/ZA200804868B/xx unknown
- 2006-12-15 KR KR1020087017186A patent/KR20080080639A/ko not_active Application Discontinuation
- 2006-12-15 TW TW095147231A patent/TW200732349A/zh unknown
- 2006-12-15 WO PCT/US2006/062173 patent/WO2007133290A2/en active Application Filing
- 2006-12-15 AR ARP060105564A patent/AR057253A1/es not_active Application Discontinuation
- 2006-12-15 BR BRPI0621065-1A patent/BRPI0621065A2/pt not_active IP Right Cessation
-
2008
- 2008-05-29 IL IL191820A patent/IL191820A0/en unknown
- 2008-06-12 CR CR10069A patent/CR10069A/es not_active Application Discontinuation
- 2008-06-13 EC EC2008008543A patent/ECSP088543A/es unknown
- 2008-07-11 MA MA31104A patent/MA30153B1/fr unknown
- 2008-07-15 NO NO20083147A patent/NO20083147L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,748 patent/US20100272738A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200732349A (en) | 2007-09-01 |
BRPI0621065A2 (pt) | 2011-11-29 |
ECSP088543A (es) | 2008-07-30 |
US7812133B2 (en) | 2010-10-12 |
WO2007133290A3 (en) | 2008-01-10 |
CA2633602A1 (en) | 2007-11-22 |
AR057253A1 (es) | 2007-11-21 |
NO20083147L (no) | 2008-09-16 |
US20090053230A1 (en) | 2009-02-26 |
KR20080080639A (ko) | 2008-09-04 |
US20100272738A1 (en) | 2010-10-28 |
MA30153B1 (fr) | 2009-01-02 |
WO2007133290A8 (en) | 2008-03-27 |
CR10069A (es) | 2008-10-10 |
AU2006343459A1 (en) | 2007-11-22 |
JP2009519718A (ja) | 2009-05-21 |
RU2008129111A (ru) | 2010-01-27 |
CN101374865A (zh) | 2009-02-25 |
EP1973949A2 (en) | 2008-10-01 |
RU2426744C2 (ru) | 2011-08-20 |
WO2007133290A2 (en) | 2007-11-22 |
IL191820A0 (en) | 2008-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272883A (en) | Monoclonal antibodies and their uses | |
ZA200804868B (en) | Anti-OX40L antibodies and methods using same | |
IL222922A (en) | Antibodies against neurophilin-1 and their use | |
HK1133441A1 (en) | Anti-mn antibodies and methods of using same | |
SI1973950T1 (sl) | Anti-EphB4 protitelesa in postopki njihove uporabe | |
AP2008004471A0 (en) | Anti-Alpha2 Intergin antibodies and their uses | |
IL182554A0 (en) | Anti-addl antibodies and uses thereof | |
IL184024A0 (en) | Irta-5 antibodies and their uses | |
EP1915177A4 (en) | ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES | |
PT2343320T (pt) | Anticorpos anti-gitr e as suas utilizações | |
IL178277A0 (en) | Irta-5 antibodies and their uses | |
IL187710A0 (en) | Anti-trkb monoclonal antibodies and uses thereof | |
EP1846032A4 (en) | LUCA2 AND ANTIBODY BINDING | |
HK1107402A1 (en) | Kid31 and antibodies that bind thereto kid31 | |
IL231891A (en) | Anti-ephrinb2 antibodies and methods for their use | |
EP1765396A4 (en) | ANTIBODY | |
ZA200703406B (en) | Anti-ADDL antibodies and uses thereof | |
GB0420466D0 (en) | Anti-glucan antibodies | |
ZA200806053B (en) | Anti-EphB4 antibodies and methods using same | |
ZA200702281B (en) | IRTA-4 antibodies and their uses | |
GB0505620D0 (en) | Methods and materials therefor | |
ZA200705716B (en) | IRTA-2 antibodies and their uses | |
GB0507219D0 (en) | Antibody and uses thereof | |
GB0507272D0 (en) | Antibody and uses thereof | |
GB0518875D0 (en) | Methods and means |